<DOC>
	<DOC>NCT02280629</DOC>
	<brief_summary>The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission in patients with ulcerative colitis (UC)</brief_summary>
	<brief_title>Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Major Signed informed consent Men or women, 18 to 70 years of age Historically confirmed diagnosis of UC by endoscopy and histology Patients being in clinical and endoscopical remission at baseline Negative pregnancy test in females of childbearing potential at baseline visit Major Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular disease associated colitis Toxic megacolon or fulminant colitis Colon resection Malabsorption syndromes Celiac disease Bleeding hemorrhoids Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding History or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack Any severe concomitant renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results Any relevant known systemic disease (e.g., AIDS, active tuberculosis) Severe comorbidity substantially reducing life expectancy History of cancer in the last five years Abnormal hepatic function at screening visit, liver cirrhosis Abnormal renal function at screening visit Patients with known hypersensitivity to soy Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP: LT02 or mesalamine) Treatment with steroids (oral, inhalative, or intravenous [IV]), cyclosporine or tacrolimus within last 4 weeks prior to randomization Treatment with methotrexate within last 6 weeks prior to randomization Treatment with TNFalphaantagonists, azathioprine, 6mercaptopurine, or antiintegrin therapy within last 8 weeks prior to randomization Treatment with rectal mesalamine or corticosteroid formulations within last 2 weeks prior to randomization Treatment with other investigational drug within last 12 weeks prior to randomization except LT02 Existing or intended pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>